RU2006105645A - Лиофилизированные композиции cci-779 - Google Patents
Лиофилизированные композиции cci-779 Download PDFInfo
- Publication number
- RU2006105645A RU2006105645A RU2006105645/15A RU2006105645A RU2006105645A RU 2006105645 A RU2006105645 A RU 2006105645A RU 2006105645/15 A RU2006105645/15 A RU 2006105645/15A RU 2006105645 A RU2006105645 A RU 2006105645A RU 2006105645 A RU2006105645 A RU 2006105645A
- Authority
- RU
- Russia
- Prior art keywords
- solution
- cci
- specified
- solvent
- butyl alcohol
- Prior art date
Links
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 title claims 17
- 229960000235 temsirolimus Drugs 0.000 title claims 16
- 239000000203 mixture Substances 0.000 title claims 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims 12
- 238000000034 method Methods 0.000 claims 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 8
- 239000002904 solvent Substances 0.000 claims 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 3
- 229930195725 Mannitol Natural products 0.000 claims 3
- 239000003085 diluting agent Substances 0.000 claims 3
- 239000012931 lyophilized formulation Substances 0.000 claims 3
- 239000000594 mannitol Substances 0.000 claims 3
- 235000010355 mannitol Nutrition 0.000 claims 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 2
- 239000000945 filler Substances 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 238000004108 freeze drying Methods 0.000 claims 1
- 239000008297 liquid dosage form Substances 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 1
- 229920000053 polysorbate 80 Polymers 0.000 claims 1
- 229940068968 polysorbate 80 Drugs 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Claims (22)
1. Раствор, пригодный для приготовления лиофилизированного CCI-779, указанный раствор содержит от 0,1 до 250 мг/мл CCI-779 и по меньшей мере 30% об./об. растворителя, выбранного из группы, состоящей из диметилсульфоксида, ацетонитрила, этанола, изопропанола, т-бутилового спирта и их смесей, которые необязательно дополнительно содержат воду.
2. Раствор по п.1, который содержит 40% об./об. воды и имеет pH от 4 до 6.
3. Раствор по п.1, который содержит от 40 до 70% об./об. растворителя.
4. Раствор по п.1, в котором растворитель содержит т-бутиловый спирт.
5. Раствор по п.1, в котором растворитель представляет собой этанол.
6. Раствор по п.4, в котором указанный растворитель, содержит т-бутиловый спирт в диапазоне от 40 до 60% об./об. т-бутилового спирта в воде.
7. Раствор по п.1, содержащий воду, где pH равен приблизительно 5,5.
8. Раствор по любому из пп.1-7, содержащий от 10 до 100 мг/мл CCI-779.
9. Раствор по любому из пп.1-7, в котором указанный раствор дополнительно содержит от 2 до 5% мас./об. наполнителя.
10. Раствор по п.9, в котором указанный наполнитель представляет собой маннит.
11. Раствор по любому из пп.1-7, в котором указанный раствор дополнительно содержит антиоксидант.
12. Способ приготовления лиофилизированной препаративной формы CCI-779, включающий стадию лиофилизации раствора по любому из пп.1-11.
13. Способ приготовления лиофилизированной препаративной формы CCI-779, включающий стадии
(a) приготовления раствора, имеющего pH от 4 до 6, и содержащего от 10 до 100 мг/мл CCI-779, 2-5% мас./об. маннита и т-бутиловый спирт в воде, и
(b) лиофилизации указанного раствора для получения лиофилизированного CCI-779.
14. Лиофилизированная препаративная форма CCI-779, полученная лиофилизацией раствора по любому из пп.1-7.
15. Способ приготовления CCI-779 для введения в жидкой форме, включающий стадию восстановления CCI-779 с помощью подходящего для парентерального введения растворителя, чтобы создать концентрированный раствор CCI-779, и смешивание указанного концентрированного раствора с разбавителем, содержащим воду, чтобы создать жидкую лекарственную форму CCI-779.
16. Способ по п.15, в котором указанный разбавитель дополнительно содержит 5-8% мас./об. полисорбата 80.
17. Способ по п.15 или 16, в котором указанный разбавитель дополнительно содержит абсолютный спирт.
18. Способ по п.15, в котором указанный концентрированный раствор разбавлен 1:9 0,9% раствором хлорида натрия.
19. Жидкая дозированная форма CCI-779, полученная способом по любому из п.15 или 16.
20. Способ повышения стабильности при хранении CCI-779, включающий стадию лиофилизации раствора, содержащего от 25 мг/мл до 100 CCI-779, т-бутиловый спирт и имеющего pH от 4 до 6.
21. Способ по п.20, в котором указанный раствор дополнительно содержит от 2 до 5% мас./об. маннита.
22. Набор, содержащий емкость для лиофилизированного CCI-779 по п.14 и растворитель для его восстановления.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49029303P | 2003-07-25 | 2003-07-25 | |
| US60/490,293 | 2003-07-25 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2006105645A true RU2006105645A (ru) | 2006-06-27 |
| RU2345772C2 RU2345772C2 (ru) | 2009-02-10 |
Family
ID=34115376
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2006105645/15A RU2345772C2 (ru) | 2003-07-25 | 2004-07-15 | Лиофилизированные композиции cci-779 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20050020615A1 (ru) |
| EP (1) | EP1648454A1 (ru) |
| JP (1) | JP2007500191A (ru) |
| KR (1) | KR20060052880A (ru) |
| CN (1) | CN1829514A (ru) |
| AR (1) | AR045094A1 (ru) |
| AU (1) | AU2004261163A1 (ru) |
| BR (1) | BRPI0412916A (ru) |
| CA (1) | CA2532251A1 (ru) |
| CO (1) | CO5680425A2 (ru) |
| CR (1) | CR8153A (ru) |
| EC (1) | ECSP066394A (ru) |
| IL (1) | IL172573A0 (ru) |
| MX (1) | MXPA05013865A (ru) |
| NO (1) | NO20056178L (ru) |
| RU (1) | RU2345772C2 (ru) |
| SG (1) | SG144165A1 (ru) |
| TW (1) | TW200505501A (ru) |
| WO (1) | WO2005011688A1 (ru) |
| ZA (1) | ZA200600684B (ru) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0313024A (pt) | 2002-07-30 | 2005-07-12 | Wyeth Corp | Formulações parenterais contendo um hidroxiéster de rapamicina |
| EP1701698B1 (en) * | 2004-01-08 | 2008-01-16 | Wyeth a Corporation of the State of Delaware | Directly compressible pharmaceutical composition for the oral admimistration of cci-779 |
| US7393952B2 (en) | 2004-08-27 | 2008-07-01 | Cordis Corporation | Solvent free amorphous rapamycin |
| US7582312B2 (en) * | 2004-11-15 | 2009-09-01 | Discovery Laboratories, Inc. | Methods to produce lung surfactant formulations via lyophilization and formulations and uses thereof |
| US7464012B2 (en) * | 2004-12-10 | 2008-12-09 | L'air Liquide, Societe Anonyme A Directoire Et Conseil De Surveillance Pour L'etude Et L'exploitation Des Procedes Georges Claude | Simplified process simulator |
| US8436190B2 (en) | 2005-01-14 | 2013-05-07 | Cephalon, Inc. | Bendamustine pharmaceutical compositions |
| US8158152B2 (en) | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
| AR072777A1 (es) | 2008-03-26 | 2010-09-22 | Cephalon Inc | Formas solidas de clorhidrato de bendamustina |
| CA2735899A1 (en) * | 2008-09-25 | 2010-04-01 | Cephalon, Inc. | Liquid formulations of bendamustine |
| CN102281877B (zh) * | 2009-01-15 | 2014-07-23 | 赛福伦公司 | 苯达莫司汀的游离碱形式 |
| WO2011151704A2 (en) * | 2010-06-02 | 2011-12-08 | Fresenius Kabi Oncology Ltd. | Stable pharmaceutical compositions of rapamycin esters |
| WO2013117969A1 (en) | 2012-02-06 | 2013-08-15 | Fresenius Kabi Oncology Ltd. | Process for preparing stable pharmaceutical compositions of compounds susceptible to hydrolysis |
| CN102940630A (zh) * | 2012-11-16 | 2013-02-27 | 浙江海正药业股份有限公司 | 含有西罗莫司酯化物的药物组合物及其制备方法 |
| WO2014118696A2 (en) * | 2013-01-29 | 2014-08-07 | Gland Pharma Limited | Pharmacuetical compositions of rapamycin esters and its derivatives |
| US10682415B2 (en) | 2013-07-22 | 2020-06-16 | Wisconsin Alumni Research Foundation | Thermogel formulation for combination drug delivery |
| CN104510708B (zh) * | 2013-09-29 | 2018-04-24 | 正大天晴药业集团股份有限公司 | 一种米铂冻干制剂及其制备方法 |
| US10342769B2 (en) | 2014-11-14 | 2019-07-09 | Navinta Iii Inc | Carmustine pharmaceutical composition |
| WO2017129772A1 (en) | 2016-01-29 | 2017-08-03 | Xellia Phamaceuticals Aps | Stable pharmaceutical compositions of temsirolimus |
| CN105687132B (zh) * | 2016-03-17 | 2020-06-12 | 鲁南贝特制药有限公司 | 一种坦西莫司注射用浓溶液及其制备方法 |
| CN107773539A (zh) * | 2016-08-27 | 2018-03-09 | 鲁南制药集团股份有限公司 | 一种注射用坦西莫司及其制备方法 |
| CN111165656A (zh) * | 2020-01-09 | 2020-05-19 | 南京大学（溧水）生态环境研究院 | 一种黑水虻冻干粉高效制备方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1204775B (it) * | 1986-01-31 | 1989-03-10 | Rosella Silvestrini | Kit per la determinazione dell'attivita' proliferativa nei tumori umani |
| US5352783A (en) * | 1993-06-09 | 1994-10-04 | Merck & Co., Inc. | Microbial transformation product having immunosuppressive activity |
| US5362735A (en) * | 1994-02-23 | 1994-11-08 | Smithkline Beecham Corporation | Rapamycin derivatives |
| US5362718A (en) * | 1994-04-18 | 1994-11-08 | American Home Products Corporation | Rapamycin hydroxyesters |
| CA2219659C (en) * | 1995-06-09 | 2008-03-18 | Novartis Ag | Rapamycin derivatives |
| GB9514594D0 (en) * | 1995-07-17 | 1995-09-13 | Johnson & Johnson Clin Diag | Chemiluminescent analytical method |
| US5780462A (en) * | 1995-12-27 | 1998-07-14 | American Home Products Corporation | Water soluble rapamycin esters |
| DE19936281C2 (de) * | 1999-08-02 | 2002-04-04 | Bayer Ag | Verfahren zur Gefriertrocknung |
| US6277983B1 (en) * | 2000-09-27 | 2001-08-21 | American Home Products Corporation | Regioselective synthesis of rapamycin derivatives |
| GB0008785D0 (en) * | 2000-04-10 | 2000-05-31 | Novartis Ag | Organic compounds |
| MXPA03001245A (es) * | 2000-08-11 | 2003-05-27 | Wyeth Corp | Metodo para el tratamiento del carcionma positivo para receptores de estrogeno. |
| US6399625B1 (en) * | 2000-09-27 | 2002-06-04 | Wyeth | 1-oxorapamycins |
| TWI286074B (en) * | 2000-11-15 | 2007-09-01 | Wyeth Corp | Pharmaceutical composition containing CCI-779 as an antineoplastic agent |
| BR0313024A (pt) * | 2002-07-30 | 2005-07-12 | Wyeth Corp | Formulações parenterais contendo um hidroxiéster de rapamicina |
| WO2004026280A2 (en) * | 2002-09-17 | 2004-04-01 | Wyeth | Granulate formulation of the rapamycin ester cci-779 |
| UA83484C2 (ru) * | 2003-03-05 | 2008-07-25 | Уайт | Способ лечения рака молочной железы комбинацией производного рапамицина и ингибитора ароматазы - летрозола, фармацевтическая композиция |
-
2004
- 2004-07-15 KR KR1020067001674A patent/KR20060052880A/ko not_active Withdrawn
- 2004-07-15 CA CA002532251A patent/CA2532251A1/en not_active Abandoned
- 2004-07-15 SG SG200804938-9A patent/SG144165A1/en unknown
- 2004-07-15 BR BRPI0412916-4A patent/BRPI0412916A/pt not_active IP Right Cessation
- 2004-07-15 EP EP04757242A patent/EP1648454A1/en not_active Withdrawn
- 2004-07-15 RU RU2006105645/15A patent/RU2345772C2/ru not_active IP Right Cessation
- 2004-07-15 CN CNA2004800214503A patent/CN1829514A/zh active Pending
- 2004-07-15 JP JP2006521942A patent/JP2007500191A/ja not_active Withdrawn
- 2004-07-15 AU AU2004261163A patent/AU2004261163A1/en not_active Withdrawn
- 2004-07-15 MX MXPA05013865A patent/MXPA05013865A/es unknown
- 2004-07-15 WO PCT/US2004/023773 patent/WO2005011688A1/en not_active Ceased
- 2004-07-19 US US10/894,210 patent/US20050020615A1/en not_active Abandoned
- 2004-07-23 AR ARP040102625A patent/AR045094A1/es unknown
- 2004-07-23 TW TW093121997A patent/TW200505501A/zh unknown
-
2005
- 2005-12-14 IL IL172573A patent/IL172573A0/en unknown
- 2005-12-15 CR CR8153A patent/CR8153A/es not_active Application Discontinuation
- 2005-12-23 NO NO20056178A patent/NO20056178L/no not_active Application Discontinuation
-
2006
- 2006-01-24 ZA ZA200600684A patent/ZA200600684B/en unknown
- 2006-02-22 CO CO06017792A patent/CO5680425A2/es unknown
- 2006-02-24 EC EC2006006394A patent/ECSP066394A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2007500191A (ja) | 2007-01-11 |
| US20050020615A1 (en) | 2005-01-27 |
| EP1648454A1 (en) | 2006-04-26 |
| RU2345772C2 (ru) | 2009-02-10 |
| TW200505501A (en) | 2005-02-16 |
| AR045094A1 (es) | 2005-10-12 |
| AU2004261163A1 (en) | 2005-02-10 |
| ECSP066394A (es) | 2006-08-30 |
| CN1829514A (zh) | 2006-09-06 |
| CA2532251A1 (en) | 2005-02-10 |
| CR8153A (es) | 2006-05-26 |
| MXPA05013865A (es) | 2006-02-28 |
| CO5680425A2 (es) | 2006-09-29 |
| SG144165A1 (en) | 2008-07-29 |
| NO20056178L (no) | 2006-02-17 |
| IL172573A0 (en) | 2006-04-10 |
| WO2005011688A1 (en) | 2005-02-10 |
| BRPI0412916A (pt) | 2006-09-26 |
| ZA200600684B (en) | 2008-07-30 |
| KR20060052880A (ko) | 2006-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2006105645A (ru) | Лиофилизированные композиции cci-779 | |
| RU2399628C2 (ru) | Производные циклоспорина, замещенные 3-эфиром и 3-тиоэфиром, для лечения и профилактики инфекционного гепатита с | |
| KR880002366B1 (ko) | 비-수성 아이버멕틴 제제 | |
| AU2009212762A1 (en) | Topical anthelmintic veterinary formulations | |
| AR033859A1 (es) | Inhibidores de la metaloproteinasa de la matriz | |
| KR920003331B1 (ko) | 활성성분으로 스페르구알린(Spergualin)을 함유하는 주사제 조성물과 그 제조방법. | |
| CO5140077A1 (es) | Complejo estable insoluble en agua, composiciones farma- ceuticas que lo contienen y metodos para su preparacion . . | |
| MXPA04010925A (es) | Formulaciones que contienen amiodarona y eter sulfoalquilico de ciclodextrina. | |
| CA2561167A1 (en) | Composition of solifenacin or salt thereof for use in solid formulation | |
| NZ285122A (en) | Stable, concentrated medicament containing docetaxel (or derivatives), at least 1 unsaturated phospholipid and small amount of at least 1 negative phospholipid | |
| CA2215327A1 (en) | Formulations for lipophilic compounds | |
| PE20030201A1 (es) | Formulacion farmaceutica de sabor enmascarado y procedimiento para su preparacion | |
| CO5560585A2 (es) | Formulacion farmaceutica para administracion intramuscular de fulvestrant | |
| DK2922530T3 (en) | Caspofunginacetatformuleringer | |
| JP5723031B2 (ja) | エキノカンジン系抗真菌剤であるミカファンギンを含む液体薬用組成物 | |
| DK2620153T3 (en) | 5 ALPHA-ANDROSTAN (ALKYL) -3 BETA, 5,6 BETA-TRIOL INJECTION AND PROCEDURE FOR PREPARING THEREOF | |
| TW200621310A (en) | A process for preparing formulations of lypophilic active substances by spray freeze drying | |
| ES2846820T3 (es) | Composición de lactonas macrocíclicas, levamisol, un aminoazúcar y un agente antiparasitario adicional | |
| CN1046516C (zh) | 化合物dx－52－1的稳定方法和其冻干组合物 | |
| EP0949923B1 (fr) | Compositions pharmaceutiques stabilisees, a base de quinupristine et de dalfopristine et leur preparation | |
| US20150265575A1 (en) | Pharmaceutical composition on the basis of phyto-nutrients with increased bioavailability, having anti-tumor activity, and method for producing said composition (alternatives) | |
| KR20210078462A (ko) | 안정한 아자시티딘-함유 약제학적 조성물의 제조방법 | |
| KR19980702109A (ko) | 인돌-카르복실산을 함유하는 비경구 투여용 제약 조성물 | |
| Barthomeuf et al. | Stabilization of Octastatin®, a somatostatin analogue: comparative accelerated stability studies of two formulations for freeze-dried products | |
| BR0302470A (pt) | Composições antiácidas lìquidas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20090716 |